Literature DB >> 31219712

Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: a retrospective radiomics study.

Emine Acar1,2, Asım Leblebici2, Berat Ender Ellidokuz3, Yasemin Başbınar4,5, Gamze Çapa Kaya6.   

Abstract

OBJECTIVE: Using CT texture analysis and machine learning methods, this study aims to distinguish the lesions imaged via 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT as metastatic and completely responded in patients with known bone metastasis and who were previously treated.
METHODS: We retrospectively reviewed the 68Ga-PSMA PET/CT images of 75 patients after treatment, who were previously diagnosed with prostate cancer and had known bone metastasis. A texture analysis was performed on the metastatic lesions showing PSMA expression and completely responded sclerotic lesions without PSMA expression through CT images. Textural features were compared in two groups. Thus, the distinction of metastasis/completely responded lesions and the most effective parameters in this issue were determined by using various methods [decision tree, discriminant analysis, support vector machine (SVM), k-nearest neighbor (KNN), ensemble classifier] in machine learning.
RESULTS: In 28 of the 35 texture analysis findings, there was a statistically significant difference between the two groups. The Weighted KNN method had the highest accuracy and area under the curve, has been chosen as the best model. The weighted KNN algorithm was succeeded to differentiate sclerotic lesion from metastasis or completely responded lesions with 0.76 area under the curve. GLZLM_SZHGE and histogram-based kurtosis were found to be the most important parameters in differentiating metastatic and completely responded sclerotic lesions.
CONCLUSIONS: Metastatic lesions and completely responded sclerosis areas in CT images, as determined by 68Ga-PSMA PET, could be distinguished with good accuracy using texture analysis and machine learning (Weighted KNN algorithm) in prostate cancer. ADVANCES IN KNOWLEDGE: Our findings suggest that, with the use of newly emerging software, CT imaging can contribute to identifying the metastatic lesions in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31219712      PMCID: PMC6732932          DOI: 10.1259/bjr.20190286

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  20 in total

1.  Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.

Authors:  Jan-Carlo Janssen; Sebastian Meißner; Nadine Woythal; Vikas Prasad; Winfried Brenner; Gerd Diederichs; Bernd Hamm; Marcus R Makowski
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

Authors:  Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; F Zattoni; Nicolas Mottet
Journal:  Eur Urol       Date:  2013-10-06       Impact factor: 20.096

3.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

4.  Identification of the most significant magnetic resonance imaging (MRI) radiomic features in oncological patients with vertebral bone marrow metastatic disease: a feasibility study.

Authors:  Laura Filograna; Jacopo Lenkowicz; Francesco Cellini; Nicola Dinapoli; Stefania Manfrida; Nicola Magarelli; Antonio Leone; Cesare Colosimo; Vincenzo Valentini
Journal:  Radiol Med       Date:  2018-09-06       Impact factor: 3.469

5.  Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.

Authors:  Rui Xu; Shoji Kido; Kazuyoshi Suga; Yasushi Hirano; Rie Tachibana; Keiichiro Muramatsu; Kazuki Chagawa; Satoshi Tanaka
Journal:  Ann Nucl Med       Date:  2014-08-09       Impact factor: 2.668

Review 6.  Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.

Authors:  Yong Joong Kim; Yong-Il Kim
Journal:  Clin Nucl Med       Date:  2018-10       Impact factor: 7.794

Review 7.  Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group.

Authors:  F E Lecouvet; J N Talbot; C Messiou; P Bourguet; Y Liu; N M de Souza
Journal:  Eur J Cancer       Date:  2014-08-16       Impact factor: 9.162

8.  The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.

Authors:  Nishikant Avinash Damle; Chandrasekhar Bal; G P Bandopadhyaya; Lalit Kumar; Praveen Kumar; Arun Malhotra; Sneh Lata
Journal:  Jpn J Radiol       Date:  2013-02-02       Impact factor: 2.374

9.  Shape, texture and statistical features for classification of benign and malignant vertebral compression fractures in magnetic resonance images.

Authors:  Lucas Frighetto-Pereira; Rangaraj Mandayam Rangayyan; Guilherme Augusto Metzner; Paulo Mazzoncini de Azevedo-Marques; Marcello Henrique Nogueira-Barbosa
Journal:  Comput Biol Med       Date:  2016-04-12       Impact factor: 4.589

Review 10.  Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.

Authors:  Louise Emmett; Kathy Willowson; John Violet; Jane Shin; Ashley Blanksby; Jonathan Lee
Journal:  J Med Radiat Sci       Date:  2017-03
View more
  8 in total

1.  Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients.

Authors:  Pierpaolo Alongi; Alessandro Stefano; Albert Comelli; Riccardo Laudicella; Salvatore Scalisi; Giuseppe Arnone; Stefano Barone; Massimiliano Spada; Pierpaolo Purpura; Tommaso Vincenzo Bartolotta; Massimo Midiri; Roberto Lagalla; Giorgio Russo
Journal:  Eur Radiol       Date:  2021-01-14       Impact factor: 5.315

2.  Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study.

Authors:  Ricarda Hinzpeter; Livia Baumann; Roman Guggenberger; Martin Huellner; Hatem Alkadhi; Bettina Baessler
Journal:  Eur Radiol       Date:  2021-09-24       Impact factor: 7.034

3.  Radiomics-based machine learning models to distinguish between metastatic and healthy bone using lesion-center-based geometric regions of interest.

Authors:  Hossein Naseri; Sonia Skamene; Marwan Tolba; Mame Daro Faye; Paul Ramia; Julia Khriguian; Haley Patrick; Aixa X Andrade Hernandez; Marc David; John Kildea
Journal:  Sci Rep       Date:  2022-06-14       Impact factor: 4.996

4.  Artificial intelligence performance in detecting tumor metastasis from medical radiology imaging: A systematic review and meta-analysis.

Authors:  Qiuhan Zheng; Le Yang; Bin Zeng; Jiahao Li; Kaixin Guo; Yujie Liang; Guiqing Liao
Journal:  EClinicalMedicine       Date:  2020-12-25

Review 5.  Effectiveness of Artificial Intelligence for Personalized Medicine in Neoplasms: A Systematic Review.

Authors:  Sorayya Rezayi; Sharareh R Niakan Kalhori; Soheila Saeedi
Journal:  Biomed Res Int       Date:  2022-04-07       Impact factor: 3.246

Review 6.  Radiomics in prostate cancer: an up-to-date review.

Authors:  Matteo Ferro; Ottavio de Cobelli; Gennaro Musi; Francesco Del Giudice; Giuseppe Carrieri; Gian Maria Busetto; Ugo Giovanni Falagario; Alessandro Sciarra; Martina Maggi; Felice Crocetto; Biagio Barone; Vincenzo Francesco Caputo; Michele Marchioni; Giuseppe Lucarelli; Ciro Imbimbo; Francesco Alessandro Mistretta; Stefano Luzzago; Mihai Dorin Vartolomei; Luigi Cormio; Riccardo Autorino; Octavian Sabin Tătaru
Journal:  Ther Adv Urol       Date:  2022-07-04

7.  A predictive model for pain response following radiotherapy for treatment of spinal metastases.

Authors:  Kohei Wakabayashi; Yutaro Koide; Takahiro Aoyama; Hidetoshi Shimizu; Risei Miyauchi; Hiroshi Tanaka; Hiroyuki Tachibana; Katsumasa Nakamura; Takeshi Kodaira
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

Review 8.  Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies.

Authors:  Simon K B Spohn; Alisa S Bettermann; Fabian Bamberg; Matthias Benndorf; Michael Mix; Nils H Nicolay; Tobias Fechter; Tobias Hölscher; Radu Grosu; Arturo Chiti; Anca L Grosu; Constantinos Zamboglou
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.